No Data
Multiple shareholders of Jinkaisheng Technology (301509.SZ) have completed their Shareholding period, collectively reducing their holdings by 4.1581 million shares.
Jin Kai Sheng Ke (301509.SZ) announced that the company's shareholder Qi Lu (Xiamen) Private Equity Investment Partnership (Limited Partnership)...
Jingkai Biotech (301509.SZ) has seen a total Shareholding reduction of 2.0688 million shares by its shareholder Qilu Investment.
Jinkai Biological Science and Technology (301509.SZ) announced that as of February 14, 2025, the company's Shareholder Qilu Investment has reduced its holdings in total...
Jinkai Biological (301509.SZ) has issued a warning of reduced earnings, expecting an annual net income of 38 million to 45 million yuan, a year-on-year decrease of 74.07%-78.11%.
Jinkai Biotechnology (301509.SZ) disclosed its performance forecast for 2024, and the company expects to belong to the Shareholder...
Jinkai Shengke: 2024 Annual Results Forecast
Jinkai Biological Science (301509.SZ): Core products are applied in the treatment fields of multiple diseases including tumors, cardiovascular and cerebrovascular diseases, diabetes, and kidney diseases.
On January 13, Gelonghui reported that Jinkaishengke (301509.SZ) stated on the investor interaction platform that the company is a small molecule CDMO service provider aimed at Global life science clients, offering customized research, development, and synthesis production services for small molecule drug intermediates and small quantities of Active Pharmaceutical Ingredient for new drug development projects of Global original drug manufacturers. The company's core products are applied in multiple disease treatment areas, including oncology, cardiovascular, diabetes, and kidney diseases.
Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509) Investors Are Less Pessimistic Than Expected